December
21
2021
Lipoprotein(a) (Lp(a)) is now being tested in-house at LifeLabs effective December 13th, 2021.
Lipoprotein(a) (Lp(a)) levels are robustly associated with the risk of coronary heart disease; strongly suggesting a causal association between Lp(a) and cardiovascular disease (CVD). In accordance with the 2021 CCS guidelines and the recently introduced Ontario Ministry of Health’s Community Access Pilot (see LifeLabs notice from December 13th, 2021), LifeLabs is now offering Lp(a) testing performed in house, at no cost to patient. The Lp(a) results are available with improved turnaround time of one day and expressed in nmol/L units. See the attached memo for more information.
Lipoprotein(a) (Lp(a)) levels are robustly associated with the risk of coronary heart disease; strongly suggesting a causal association between Lp(a) and cardiovascular disease (CVD). In accordance with the 2021 CCS guidelines and the recently introduced Ontario Ministry of Health’s Community Access Pilot (see LifeLabs notice from December 13th, 2021), LifeLabs is now offering Lp(a) testing performed in house, at no cost to patient. The Lp(a) results are available with improved turnaround time of one day and expressed in nmol/L units. See the attached memo for more information.
Lipoprotein(a) (Lp(a)) is now being tested in-house at LifeLabs effective December 13th, 2021.
Lipoprotein(a) (Lp(a)) levels are robustly associated with the risk of coronary heart disease; strongly suggesting a causal association between Lp(a) and cardiovascular disease (CVD). In accordance with the 2021 CCS guidelines and the recently introduced Ontario Ministry of Health’s Community Access Pilot (see LifeLabs notice from December 13th, 2021), LifeLabs is now offering Lp(a) testing performed in house, at no cost to patient. The Lp(a) results are available with improved turnaround time of one day and expressed in nmol/L units. See the attached memo for more information.
